Parkwalk have been named in the list of most active investors who led or co-led series A or B deal in Europe in Crunchbase News’s report on ‘Europe’s Most Active Startup Investors In 2021′. Funding into Europe’s startups in 2021 grew by more than 100 percent year over year with increased funding at every stage, according to Crunchbase data. Parkwalk joined an impressive list of investors that led or co-led Series A or B rounds in European companies in 2021.
Not only does this report highlight that Parkwalk are seeing increased good quality and quantity deal flow, but it further exemplifies our investment strategy focus on our co-investment model, meaning we are able to participate in larger and later stage funding rounds with well known institutional names including L&G, BGF Ventures, Amadeus and Ocado Group. Giving our clients access to larger funding rounds in deals they wouldn’t otherwise gain access to.
We offer investors a diversified portfolio of investments, spread across sectors and investment stages. Below are recent deals highlighting this and the types of deals our EIS investors participate in:
- £27m Series B for Petmedix, a leader in the emerging companion animal antibody field
- £16m Series B for Brainomix, an AI-powered stroke imaging software company
- $10m Series A for Charco Neurotech, a wearable device to treat Parkinson’s symptoms
Our current fund offerings includes our Knowledge Intensive EIS Fund II which will invest in 10+ knowledge intensive EIS qualifying companies across a range of investment stages from Series A-C. This fund closes on 1st April 2022. If you’d like to find out more about the fund, please click here or contact our sales team on email@example.com or 020 7759 2285.
Parkwalk Advisors Limited (Parkwalk) is authorised and regulated by the Financial Conduct Authority: FRN 502237. Investments referred to in this news article are not suitable for all investors. Capital is at risk and investors may not get back the full amount invested. Tax reliefs subject to individual circumstances. Any investment in a Parkwalk product must only be made on the basis of the terms of the full Information Memorandum. Tax treatment depends on the individual circumstances of each investor. Parkwalk is not able to provide advice as to the suitability of investing in any product.